Leerink Partners Starts Nabriva Therapeutics AG (NBRV) at Outperform

Leerink Partners initiates coverage on Nabriva Therapeutics AG (NASDAQ: NBRV) with a Outperform rating and a price target of $19.00.

Analyst Paul Matteis commented, "We are initiating on NBRV with an Outperform rating and a $19 price target per ADS. Nabriva is a biotechnology company developing lead product Lefamulin as an intravenous (IV) and oral therapy for Community Acquired Bacterial Pneumonia (CABP). We believe Nabriva is unique among its late stage antibiotic peers (CEMP [MP], PRTK [OP], TTPH) – while multiple other companies are focused on improved, next-generation agents from well-established antibiotic classes such as macrolides and tetracyclines, Lefamulin is a "pleuromutilin," a novel anti-infective with a new mechanism of action. While this implies slightly higher risk to Phase III, because of Lefamulin's differentiation, we believe NBRV offers potentially greater reward upon success. MEDACorp KOLs are very enthusiastic about Lefamulin's clinical potential, as a novel mechanism-of-action implies little to no risk of pre-existing resistance and just as important, effectiveness against problematic, resistant bacterial strains. Also, as a member of a new class, Lefamulin reimbursement may be easier given the lack of generic comps (i.e., no gx pleuromutilins)."

For an analyst ratings summary and ratings history on Nabriva Therapeutics AG click here. For more ratings news on Nabriva Therapeutics AG click here.

Shares of Nabriva Therapeutics AG closed at $10.00 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Roth/MKM Out Positive on Bio-Path Holdings (BPTH), PT $40
• Citi Out Defending Micron Technology (MU): 'We would buy the stock on any weakness'